|
1
|
Kamangar F, Dores GM and Anderson WF:
Patterns of cancer incidence, mortality, and prevalence across five
continents: Defining priorities to reduce cancer disparities in
different geographic regions of the world. J Clin Oncol.
24:2137–2150. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hartgrink HH, Jansen EP, van Grieken NC
and van de Velde CJ: Gastric cancer. Lancet. 374:477–490. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J,
Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin.
58:71–96. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
WaIlg B, Doellch JG and Novina CD:
Analysis of microRNA effector functions in vitro. Methods.
43:91–104. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Stark A, Brennecke J, Bushati N, Russell
RB and Cohen SM: Animal MicroRNAs confer robustness to gene
expression and have a significant impact on 3′UTR evolution. Cell.
123:1133–1146. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ambros V: The function of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kloosterman WP and Plasterk RH: The
diverse functions of microRNAs in animal development and disease.
Dev Cell. 11:441–450. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Manikandan J, Aarthi JJ, Kumar SD and
Pushparaj PN: Oncomirs: The potential role of non-coding microRNAs
in understanding cancer. Bioinformation. 2:330–334. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Volinia S, Calin GA, Liu CG, Ambs S,
Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et
al: A microRNA expression signature of human solid tumors defines
cancer gene targets. Proc Natl Acad Sci USA. 103:2257–2261. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Esquela-Kerscher A and S1ack FJ:
Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer.
6:259–269. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nairz K, Rottig C, Rintelen F, Zdobnov E,
Moser M and Hafen E: Overgrowth caused by misexpression of a
mciroRNA with dispensable wild-type function. DevBiol. 291:314–324.
2006.
|
|
13
|
Hurst DR, Edmonds MD and Welch DR:
Metastamir: The field of metastasis- regulatory microRNA is
spreading. Cancer Res. 69:7495–7498. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bockhorn J, Yee K, Chang YF, Prat A, Huo
D, Nwachukwu C, Dalton R, Huang S, Swanson KE, Perou CM, et al:
MicroRNA-30c targets cytoskeleton genes involved in breast cancer
cell invasion. Breast Cancer Res Treat. 137:373–382. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kong X, Xu X, Yan Y, Guo F, Li J, Hu Y,
Zhou H and Xun Q: Estrogen regulates the tumour suppressor
MiR-30cand its target gene, MTA-1, in endometrial cancer. PLoS One.
9:e908102014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Garofalo M, Romano G, Di Leva G, Nuovo G,
Jeon YJ, Ngankeu A, Sun J, Lovat F, Alder H, Condorelli G, et al:
EGFR and MET receptor tyrosine kinase-altered microRNA expression
induces tumorigenesis and gefitinib resistance in lung cancers. Nat
Med. 18:74–82. 2012. View
Article : Google Scholar
|
|
17
|
Zhang Q, Yu L, Qin D, Huang R, Jiang X,
Zou C, Tang Q, Chen Y, Wang G, Wang X and Gao X: Role of
microRNA-30c targeting ADAM19 in colorectal cancer. PloS One.
10:e01206982015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jiuyu G: Discovery and mechanism of NK
cell killing new tumor cell immune molecules. PhD dissertation, The
Fourth Military Medical University. 2012.
|
|
19
|
Goparaju CM, Blasberg JD, Volinia S,
Palatini J, Ivanov S, Donington JS, Croce C, Carbone M, Yang H and
Pass HI: Onconase mediated NFKβ downregulation in malignant pleural
mesothelioma. Oncogene. 30:2767–2777. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rodríguez-González FG, Sieuwerts AM, Smid
M, Look MP, Meijer-van Gelder ME, de Weerd V, Sleijfer S, Martens
JW and Foekens JA: MicroRNA-30c expression level is an independent
predictor of clinical benefit of endocrine therapy in advanced
estrogen receptor positive breast cancer. Breast Cancer Res Treat.
127:43–51. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gu YF, Zhang H, Su D, Mo ML, Song P, Zhang
F and Zhang SC: miR-30b and miR-30c expression predicted response
to tyrosine kinase inhibitors as first line treatment in non-small
cell lung cancer. Chin Med J (Engl). 126:4435–4439. 2013.PubMed/NCBI
|
|
22
|
Mu YP, Tang S, Sun WJ, Gao WM, Wang M and
Su XL: Association of miR-193b down-regulation and miR-196a
up-regulation with clinicopathological features and prognosis in
gastric cancer. Asian Pac J Cancer Prev. 15:8893–8900. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cancer staging, . National Cancer
Institute. Retrieved. 04–January;2013.
|
|
24
|
Takaishi S, Okumura T, Tu S, Wang SS,
Shibata W, Vigneshwaran R, Gordon SA, Shimada Y and Wang TC:
Identification of gastric cancer stem cells using the cell surface
marker CD44. Stem Cells. 27:1006–1020. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Byun DS, Lee MG, Chae KS, Ryu BG and Chi
SG: Frequent epigenetic inactivation of RASSF1A by aberrant
promoter hypermethylation in human gastric adenocarcinoma. Cancer
Res. 61:7034–7038. 2001.PubMed/NCBI
|
|
26
|
Pan J, Hu H, Zhou Z, Sun L, Peng L, Yu L,
Sun L, Liu J, Yang Z and Ran Y: Tumor-suppressive mir-663 gene
induces mitotic catastrophe growth arrest in human gastric cancer
cells. Oncol Rep. 24:105–112. 2010.PubMed/NCBI
|
|
27
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Method. 25:402–408. 2001.
View Article : Google Scholar
|
|
28
|
Ling XH, Han ZD, Xia D, He HC, Jiang FN,
Lin ZY, Fu X, Deng YH, Dai QS, Cai C, et al: MicroRNA-30c serves as
an independent biochemical recurrence predictor and potential tumor
suppressor for prostate cancer. Mol Biol Rep. 41:2779–2788. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yu F, Deng H, Yao H, Liu Q, Su F and Song
E: Mir-30 reduction maintains self-renewal and inhibits apoptosis
in breast tumor-initiating cells. Oncogene. 29:4194–4204. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Martinez I, Cazalla D, Almstead LL, Steitz
JA and DiMaio D: miR-29 and miR-30 regulate B-Myb expression during
cellular senescence. Proc Natl Acad Sci USA. 108:522–527. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhong Z, Xia Y, Wang P, Liu B and Chen Y:
Low expression of microRNA-30c promotes invasion by inducing
epithelial mesenchymal transition in non-small cell lung cancer.
Mol Med Rep. 10:2575–2579. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Polakis P: Wnt signaling and cancer. Genes
Dev. 14:1837–1851. 2000.PubMed/NCBI
|
|
33
|
Mieszczanek J, de la Roche M and Bienz M:
A role of Pygopus as an anti-repressor in facilitating
Wnt-dependent transcription. Proc Natl Acad Sci USA.
105:19324–19329. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Brembeck FH, Rosário M and Birchmeier W:
Balancing cell adhesion and Wnt signaling, the key role of
beta-actenin. Curr Opin Genet Dev. 16:51–59. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Miller TC, Rutherford TJ, Johnson CM,
Fiedler M and Bienz M: Allosteric remodelling of the histone H3
binding pocket in the Pygo2 PHD finger triggered by its binding to
the B9L/BCL9 co-factor. J Mol Biol. 401:969–984. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Liu X and Wan Y: Wnt signaling pathway and
tumor. J Cancer Prog. 7:296–300. 2009.
|
|
37
|
Shuai W, Caiquan Z and Zhao L: The
Expression of BCL9 and VEGF in Colorectal Cancer and Their Clinical
Significance. Life Science Research. 14:246–249. 2010.
|
|
38
|
Mani M, Carrasco DE, Zhang Y, Takada K,
Gatt ME, Dutta-Simmons J, Ikeda H, Diaz-Griffero F, Pena-Cruz V,
Bertagnolli M, et al: BCL9 promotes tumor progression by conferring
enhanced proliferative, metastatic, and angiogenic properties to
cancer cells. Cancer Res. 69:7577–7586. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Deka J, Wiedemann N, Anderle P,
Murphy-Seiler F, Bultinck J, Eyckerman S, Stehle JC, André S,
Vilain N, Zilian O, et al: Bcl9/Bcl9l are critical for Wnt-mediated
regulation of stem cell traits in colon epithelium and
adenocarcinomas. Cancer Res. 70:6619–6628. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Jia W, Eneh JO, Ratnaparkhe S, Altman MK
and Murph MM: MicroRNA-30c-2* expressed in ovarian cancer cells
suppresses growth factor-induced cellular proliferation and
downregulates the oncogene BCL9. Mol Cancer Res. 9:1732–1745. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ling XH, Chen ZY, Luo HW, Liu ZZ, Liang
YK, Chen GX, Jiang FN and Zhong WD: BCL9, a coactivator for
Wnt/β-catenin transcription, is targeted by miR-30c and is
associated with prostate cancer progression. Oncol Lett.
11:2001–2008. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhao JJ, Lin J, Zhu D, Wang X, Brooks D,
Chen M, Chu ZB, Takada K, Ciccarelli B, Admin S, et al: miR-30-5p
functions as a tumor suppressor and novel therapeutic tool by
targeting the oncogenic Wnt/β-catenin/BCL9 pathway. Cancer Res.
74:1801–1813. 2014. View Article : Google Scholar : PubMed/NCBI
|
